Translational Safety & Bioanalytical Sciences, Amgen Research, Amgen Inc, One Amgen Center Drive, Thousand Oaks, California, 91320, USA.
Pharmacokinetics & Drug Metabolism, Amgen Research, Amgen Inc, One Amgen Center Drive, Thousand Oaks, California, 91320, USA.
AAPS J. 2022 Nov 14;24(6):116. doi: 10.1208/s12248-022-00770-6.
The aim of this research was to develop a reliable non-radiometric method to measure the residual blood in tissue without the need for perfusion or radiometric measurements in biodistribution studies. It was found that the perfusion method not only was ineffective in removing blood from tissue, but also introduced additional variability in the determination of tissue drug exposure and was not reproducible across studies. In addition, the use of hemoglobin as an endogenous protein and biomarker for tissue blood content was studied and it was found that hemoglobin measurement in tissue was not a reliable and effective approach for determination of residual blood level in tissue. To evaluate an alternative method for addressing the tissue blood level in biodistribution studies, animals were dosed with a Residual Blood Determinant Reagent (RBDR) 5 min prior to tissue harvesting. The level of RBDR, an exogenous protein, was measured in whole blood homogenate and in tissue lysate. Based on the level of the RBDR, the vascular blood volume (VBV) in tissue was calculated and then the tissue exposures were corrected based on the blood volumes. The tissue VBVs measured by the RBDR method were comparable with the literature values obtained by radiometric measurements.
本研究旨在开发一种可靠的非放射性方法来测量组织中的残留血液,而无需在生物分布研究中进行灌注或放射性测量。研究发现,灌注方法不仅不能有效地从组织中去除血液,而且还会导致组织中药物暴露的测定产生额外的变异性,并且在不同研究中不可重现。此外,还研究了血红蛋白作为组织血液含量的内源性蛋白质和生物标志物的用途,结果发现血红蛋白在组织中的测量不是确定组织中残留血液水平的可靠有效方法。为了评估替代方法来解决生物分布研究中的组织血液水平问题,在组织收获前 5 分钟,向动物给予残留血液测定试剂 (RBDR)。在外源性蛋白质全血匀浆和组织裂解物中测量 RBDR 的水平。基于 RBDR 的水平,计算组织中的血管血液体积 (VBV),然后根据血液体积校正组织暴露。RBDR 方法测量的组织 VBV 与通过放射性测量获得的文献值相当。